Latest Breaking News On - ரட்ஜர்ஸ் ராபர்ட் மரம் ஜான்சன் பள்ளி ஆஃப் மருந்து - Page 1 : comparemela.com

Credit: Getty Images. The Food and Drug Administration (FDA) has approved Twyneo ® (tretinoin 0.1% and benzoyl peroxide 3%) cream for the topical treatment of acne vulgaris in patients 9 years of age and older. Twyneo is a fixed-dose combination of tretinoin 0.1%, a retinoid, and benzoyl peroxide 3%, a topical antibacterial. The formulation of Twyneo uses silica core shell structures to separately microencapsulate tretinoin crystals and benzoyl peroxide crystals enabling inclusion of the 2 active ingredients in the cream. “Twyneo combines, for the first time, 2 of the most commonly used topical agents available for the treatment of acne into a single application,” said Hilary Baldwin, MD, Clinical Associate Professor of Dermatology, Rutgers Robert Wood Johnson School of Medicine, Medical Director, The Acne Treatment and Research Center and Past President of the American Acne and Rosacea Society. “Due to stability issues, these products don’t play well

United statesHilary baldwinGel technologies incDrug administrationResearch centerRutgers robert wood johnson school of medicineRosacea societyClinical associate professorRutgers robert wood johnson schoolMedical directorAcne treatmentPast presidentAmerican acneGlobal assessmentGel technologiesAccessed july